1. Home
  2. BRZE vs ZYME Comparison

BRZE vs ZYME Comparison

Compare BRZE & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Braze Inc.

BRZE

Braze Inc.

HOLD

Current Price

$20.65

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$27.35

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRZE
ZYME
Founded
2011
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
BRZE
ZYME
Price
$20.65
$27.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
28
11
Target Price
$38.04
$38.90
AVG Volume (30 Days)
2.9M
531.5K
Earning Date
03-24-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
$738,182,000.00
$105,965,000.00
Revenue This Year
$22.69
$162.82
Revenue Next Year
$16.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.40
38.87
52 Week Low
$15.26
$9.40
52 Week High
$37.67
$28.49

Technical Indicators

Market Signals
Indicator
BRZE
ZYME
Relative Strength Index (RSI) 46.77 69.45
Support Level $17.98 $22.28
Resistance Level $20.53 $28.49
Average True Range (ATR) 1.29 0.96
MACD -0.01 0.30
Stochastic Oscillator 43.51 100.00

Price Performance

Historical Comparison
BRZE
ZYME

About BRZE Braze Inc.

Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates majority of its revenue from the United States.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: